scholarly journals Inhibitory effect of AD-1590, a non-steroidal anti-inflammatory drug, on allergic inflammation in mice and rats.

1988 ◽  
Vol 92 (1) ◽  
pp. 29-38 ◽  
Author(s):  
Hideo NAKAMURA ◽  
Satoru MOTOYOSHI ◽  
Katsumi ISHII ◽  
Toshiaki KADOKAWA
2013 ◽  
Vol 2013 ◽  
pp. 1-10 ◽  
Author(s):  
P. Skopiński ◽  
B. J. Bałan ◽  
J. Kocik ◽  
R. Zdanowski ◽  
S. Lewicki ◽  
...  

Anticancer activity of many herbs was observed for hundreds of years. They act as modifiers of biologic response, and their effectiveness may be increased by combining multiple herbal extracts . PERVIVO, traditional digestive herbal remedy, contains some of them, and we previously described its antiangiogenic activity. Numerous studies documented anticancer effects of nonsteroidal anti-inflammatory drugs. We were the first to show that sulindac and its metabolites inhibit angiogenesis. In the present paper the combinedin vivoeffect of multicomponent herbal remedy PERVIVO and nonsteroidal anti-inflammatory drug sulindac on tumor growth, tumor angiogenesis, and tumor volume in Balb/c mice was studied. These effects were checked after grafting cells collected from syngeneic sarcoma L-1 tumors into mice skin. The strongest inhibitory effect was observed in experimental groups treated with PERVIVO and sulindac together. The results of our investigation showed that combined effect of examined drugs may be the best way to get the strongest antiangiogenic and antitumor effect.


1991 ◽  
Vol 12 (10) ◽  
pp. 1949-1952 ◽  
Author(s):  
Takuji Tanaka ◽  
Toshihiro Kojima ◽  
Naoki Yoshimi ◽  
Shigeyuki Sugie ◽  
Hideki Mori

Medicina ◽  
2012 ◽  
Vol 48 (12) ◽  
pp. 90 ◽  
Author(s):  
Mehmet Demir ◽  
Mehmet Horoz ◽  
Turgay Ulas ◽  
Mehmet Eren ◽  
Zafer Ercan

Hyponatremia (serum sodium level, <135 mmol/L) occasionally may develop in the course of treatment with nonsteroidal anti-inflammatory drugs, which are usually used in daily clinical practice. Nonsteroidal anti-inflammatory drugs diminish the normal inhibitory effect of prostaglandins on the activity of antidiuretic hormone and can therefore reduce free water excretion, leading to water retention and induction or exacerbation of hyponatremia. In this report, we present a case of hyponatremia in a 78-year-old man who had received meloxicam, a nonsteroidal anti-inflammatory drug.


Author(s):  
Nia Samira ◽  
Benarous Khedidja ◽  
Abdelalim Fatima Zahra ◽  
Chellali Khadidja Nour Elyakine ◽  
Yousfi Mohamed

Background: For the first time, the anti-inflammatory drug betamethasone is investigated for its inhibitory activity against lipase. Objective: This work aims to demonstrate the in vitro and in silico inhibitory effect of the anti-inflammatory drug betamethasone on the enzymatic activity of two lipases. Methods: In vitro study using p-nitrophenyllaurate as lipase substrate is used to determine inhibition potency. Molecular Docking is performed using the Autodock Vina for drug molecule and two enzymes Candida rugosa lipase and human pancreatic lipase. Results: Betamethasone represents a moderate inhibition effect with a value of IC50 of 0.36±0.01 mg/ml. Molecular docking allowed us to understand inhibitory – enzyme interactions and to confirm in vitro obtained results. Conclusion: These experiments showed that betamethasone can be used in the treatment of diseases related to lipase activity.


1996 ◽  
Vol 71 ◽  
pp. 304
Author(s):  
Keiko Ogino ◽  
Yoshiteru Harada ◽  
Michiko Kawamura ◽  
Ko Hatanaka ◽  
Saori Tsuda ◽  
...  

1998 ◽  
Vol 95 (5) ◽  
pp. 603-609 ◽  
Author(s):  
Marijke HAAS ◽  
Frits MOOLENAAR ◽  
Dirk K. F. MEIJER ◽  
Paul E. DE JONG ◽  
Dick DE ZEEUW

1.Renal specific targeting of the non-steroidal anti-inflammatory drug naproxen was obtained by coupling to the low-molecular-mass protein lysozyme. A previous study showed that conjugation to lysozyme resulted in a 70-fold increase of naproxen accumulation in the kidney with a subsequent renal release of the active metabolite naproxen–lysine. 2.In the present study we questioned whether naproxen–lysozyme is active in the rat kidney, inhibiting the urinary excretion of prostaglandin E2 and renal sodium and water excretion in salt-restricted baseline conditions as well as during frusemide treatment. 3.A high dose of free naproxen (10 ;mg·day-1·kg-1) did not affect prostaglandin E2 excretion in baseline conditions (naproxen, 11±1 ;ng/8 ;h; vehicle, 13±4 ;ng/8 ;h), whereas sodium and water excretion were, respectively, 3.0 and 1.6 times lower in the naproxen group (P< 0.05). Naproxen completely prevented the frusemide-induced increase (3-fold) in prostaglandin E2 excretion (naproxen 6.6±1.1 ;ng/8 ;h, vehicle 40±12 ;ng/8 ;h, P< 0.005). Frusemide-stimulated natriuresis and diuresis were, respectively, 1.6 (P< 0.05) and 1.8 times (P< 0.005) lower in the naproxen group. 4.A dose of 2 ;mg·day-1·kg-1 lysozyme-conjugated naproxen did not affect prostaglandin E2 excretion in baseline conditions (conjugate, 18±2 ;ng/8 ;h; vehicle, 24±5 ;ng/8 ;h). The conjugate also had no effect on sodium and water excretion. However, the naproxen conjugate completely prevented the frusemide-induced increase (2-fold) in prostaglandin E2 excretion (conjugate, 16±3 ;ng/8 ;h; vehicle, 48±13 ;ng/8 ;h, P< 0.05). Surprisingly, frusemide-induced natriuresis and diuresis were not affected by the conjugate. 5.In conclusion, a renal specific delivery of the non-steroidal anti-inflammatory drug naproxen using lysozyme results in an inhibitory effect on renal prostaglandin E2 synthesis but does not affect the excretion of sodium and water, in contrast to free naproxen.


Sign in / Sign up

Export Citation Format

Share Document